^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD38 expression

    i
    Other names: CD38, CD38 Molecule, ADP-Ribosyl Cyclase 1, ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1, 2'-Phospho-Cyclic-ADP-Ribose Transferase, 2'-Phospho-ADP-Ribosyl Cyclase, Cyclic ADP-Ribose Hydrolase 1, NAD(+) Nucleosidase, CD38 Antigen (P45), ADPRC 1, 2'-Phospho-ADP-Ribosyl Cyclase/2'-Phospho-Cyclic-ADP-Ribose Transferase, Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase, Cluster Of Differentiation 38, CADPr Hydrolase 1, CD38 Antigen, ADPRC1, T10
    Entrez ID:
    952
    Related biomarkers:
    Expression
    Others
    8d
    IG-20541: Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=40, Completed, University of Turin, Italy | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Dec 2024 | Trial primary completion date: Jul 2025 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • CD55 (CD55 Molecule) • CD59 (CD59 Molecule)
    |
    CD38 expression
    23d
    Dysregulated CD38 expression on T cells was associated with rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 positive dermatomyositis. (PubMed, Front Immunol)
    Dysregulated CD38 expression on T cell subsets was associated with lung involvement, especially RP-ILD in MDA5+ DM patients. CD38+ T cell subsets could be used as potential biomarkers for predicting ILD/RP-ILD in MDA5+ DM patients.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • IFIH1 (Interferon Induced With Helicase C Domain 1) • IFNA1 (Interferon Alpha 1)
    |
    CD38 expression
    29d
    CD56briCD38+ as a novel neutrophil-specific marker in chronic myeloid leukemia. (PubMed, Heliyon)
    Moreover, this increase disappears in CML patients after treatment with tyrosine kinase inhibitors when the curative effect was satisfactory. We conclude that an increase in the proportion of CD56briCD38+ neutrophil subsets exceeding 2.0 % of total neutrophils serves as a highly sensitive and specific flow cytometry marker, enabling rapid and accurate identification of CML.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • CD38 (CD38 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    BCR-ABL1 fusion • CD38 expression • NCAM1 expression
    1m
    Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma. (PubMed, Hemasphere)
    In the preclinical setting, MT-0169 effectively lysed primary MM cells from newly diagnosed and heavily pretreated MM patients, including those refractory to daratumumab, with minimal toxicity against nonmalignant hematopoietic cells. Finally, MT-0169 showed efficient in vivo anti-MM activity in various mouse xenograft models, including one in which MM cells are grown in a humanized bone marrow-like niche. These findings support clinical investigation of MT-0169 in relapsed/refractory MM patients, including those refractory to CD38-targeting immunotherapies.
    Preclinical • Journal • IO biomarker
    |
    CASP3 (Caspase 3) • CASP7 (Caspase 7)
    |
    CD38 expression
    |
    Darzalex (daratumumab) • MT-0169
    1m
    Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide (ASH 2024)
    Conclusions : Tal-DP exhibits a deep, long-term impact on efficacy through complementary mechanisms of action and may be especially beneficial in pts with prior BsAb exposure, who typically have unfavorable BL immune profiles. Ongoing analyses of tec-DP from MajesTEC-2 (NCT04722146) will be presented.
    Clinical • PK/PD data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    CD38 expression • CD8 expression • LAG3 expression
    |
    Darzalex (daratumumab) • pomalidomide • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity. (PubMed, Mol Ther Oncol)
    Together, this highlights CD38 as an important regulator of CD45 activity via CD43 and galectin-1, in turn acting as a positive modulator of CLL proliferation. Ultimately, the CD38/CD45 molecular hub could be an important therapeutic target in CLL.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • LGALS1 (Galectin 1) • SPN (Sialophorin)
    |
    CD38 expression • PTPRC expression
    2ms
    The role of the CLL-1 protein in disease monitoring in patients diagnosed with acute myeloid leukaemia and myelodysplastic syndrome. (PubMed, Pol J Pathol)
    The aim of this study was to evaluate, using multi-colour flow cytometry, the level of CLL-1 protein expression on CD34+CD38- myeloid niche cells in acute myeloid leukaemia (AML) and myelodysplastic syndromepatients at the time of diagnosis and during disease monitoring on the example of 3 practical cases. The following conclusion was drawn: CD34+CD38-CLL-1+ cells in AML patients may serve as a biomarker to predict disease aggressiveness.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule) • CD34 (CD34 molecule)
    |
    CD38 expression
    2ms
    FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=9, Completed, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2025 --> Oct 2024 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538
    2ms
    Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro. (PubMed, Brain Behav Immun Health)
    However, plasma cells were largely unchanged, and NK-cells expressing CD38 - the daratumumab target antigen - increased in blood. Future research should consider the optimal timings of exercise during daratumumab treatment in myeloma to avert exacerbation of daratumumab-mediated NK-cell lysis.
    Preclinical • Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD14 (CD14 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    CD38 expression
    |
    Darzalex (daratumumab)
    3ms
    Increased abundance of Firmicutes and depletion of Bacteroidota predicts poor outcome in chronic lymphocytic leukemia. (PubMed, Oncol Lett)
    Finally, the present study suggested the log Firmicutes/Bacteroidota ratio as a novel intestinal microbiome signature associated with a shorter time to first treatment in individuals with CLL. The findings indicate that oral and gut microbial diversity in CLL might point to the inflammatory-related modulation of the clinical course of the disease.
    Journal • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus) • CD38 (CD38 Molecule)
    |
    CD38 expression • IGH mutation
    3ms
    Expression and diagnostic value of lymphocyte subsets and activation status in non-Hodgkin's lymphoma-associated hemophagocytic lymphohistiocytosis (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Specifically, absolute counts of NK cells ≤72.0 cells/μl, CD4(+)CD28(+)/CD4(+) T >94.2%, and CD8(+)CD28(+)/CD8(+) T >38.4% were identified as risk factors for predicting the development of NHL-HLH patients. This will assist in early clinical diagnosis and treatment.
    Retrospective data • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • CD28 (CD28 Molecule)
    |
    CD38 expression • CD8 expression • CD28 expression • CD4 expression
    3ms
    CD146 Molecule Expression in B Cells Acute Lymphoblastic Leukemia (B-ALLs): A Flow-Cytometric Marker for an Accurate Diagnostic Workup. (PubMed, Mediterr J Hematol Infect Dis)
    Our data demonstrate the association between CD146 expression and Ph+ ALLs. CD146, along with myeloid markers, may help to identify a distinctive immunophenotypic pattern, useful for rapid identification in the diagnostic routine of this subtype of B-ALLs that benefits from a specific therapeutic approach.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • CD38 (CD38 Molecule) • CD33 (CD33 Molecule) • MCAM (Melanoma Cell Adhesion Molecule) • CEACAM6 (CEA Cell Adhesion Molecule 6) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    CD38 expression
    3ms
    Flow cytometric immunophenotypic features of acute myeloid leukemia with mast cell differentiation. (PubMed, Am J Clin Pathol)
    The MCs in AML-MC cases are characterized by dim CD45, low side scatter, CD34 and CD123 positivity, and uniform and increased CD38 expression. Flow cytometry is an excellent tool for identifying AML-MC cases.
    Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    CD38 expression • CD123 positive • NCAM1 expression • CD34 positive
    5ms
    IMMUNOREACT 11: IMMUNE PREDICTORS OF RELAPSE AFTER ADJUVANT THERAPY IN RECTAL CANCER PATIENTS (UEGW 2024)
    Our preliminary data suggest that the immune-related markers signature in the healthy peritumoral mucosa might be useful for predicting relapse after adjuvant therapy in rectal cancer patients. Moreover, relapsing patients showed lower stimulation of macrophages and lymphocytes, thus suggesting that impaired immune surveillance might influence adjuvant therapy outcomes. Sampling healthy mucosa might help the decision-making about adjuvant therapy after surgery for rectal cancer.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD28 (CD28 Molecule) • CCL8 (C-C Motif Chemokine Ligand 8) • FOXP3 (Forkhead Box P3) • TNFSF13B (TNF Superfamily Member 13b) • IL1R1 (Interleukin 1 receptor, type I) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20) • SIGLEC1 (Sialic Acid Binding Ig Like Lectin 1) • MS4A6A (Membrane Spanning 4-Domains A6A)
    |
    CD38 expression • IL2RA expression • CD8-H
    |
    nCounter® PanCancer IO 360™ Panel
    7ms
    Clinical Characteristics and Diagnosis of Ph-Positive Mixed Phenotype Acute Leukemia. (PubMed, Clin Lab)
    Mixed phenotype acute leukemia (MPAL) is a rare type of malignant hematologic disease. Its diagnosis is based on the comprehensive evaluation of bone marrow cell morphology, immunophenotype, molecular and cytogenetic features.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD9 (CD9 Molecule) • MME (Membrane Metalloendopeptidase) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ANPEP (Alanyl Aminopeptidase, Membrane) • MPO (Myeloperoxidase)
    |
    CD38 expression • CD19 expression • CD123 expression • IL3RA expression
    7ms
    Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands. (PubMed, Int J Mol Sci)
    In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.
    Journal • IO biomarker
    |
    MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    CD38 expression
    |
    Darzalex (daratumumab) • tinostamustine (EDO-S101)
    8ms
    Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia. (PubMed, JCI Insight)
    Potent DHODHi to date have been limited by their therapeutic index; however, we introduce pharmacodynamic monitoring to predict tolerability while preserving antitumor activity. We additionally suggest that DHODHi is effective at lower doses with select immune therapies, widening the therapeutic index.
    Journal • IO biomarker
    |
    CD47 (CD47 Molecule)
    |
    CD38 expression
    8ms
    Small-molecule α-lipoic acid targets ELK1 to balance human neutrophil and erythrocyte differentiation. (PubMed, Stem Cell Res Ther)
    ALA and ELK1 are found to regulate both human granulopoiesis and erythropoiesis via RNA spliceosome, and ALA-ELK1 signal might be the target of human leukemia therapy.
    Journal • IO biomarker
    |
    SF3B1 (Splicing Factor 3b Subunit 1) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CD37 (CD37 Molecule) • ELK1 (ETS Transcription Factor ELK1)
    |
    CD38 expression • TFRC expression • CD37 expression
    9ms
    Arginase 2 is a Diagnostic and Prognostic Marker for Prostate Cancer and Is Associated with Metabolism. (PubMed, Altern Ther Health Med)
    Furthermore, based on the effect of ARG2 on the malignant phenotype of PCa in vitro, we also found that ARG2 may be a tumor suppressor that plays an important role in inhibiting proliferation, migration, and invasion. These findings suggest that ARG2 has been tentatively identified as a new target for research into how PCa develops in metabolism and for the development of innovative targeted treatments.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule) • ARG2 (Arginase 2)
    |
    CD38 expression
    9ms
    Role of CD38 in anti-tumor immunity of small cell lung cancer. (PubMed, Front Immunol)
    A combination of cisplatin/etoposide, ICB, and CD38 blockade delayed tumor growth compared to cisplatin/etoposide. Our study provides a preliminary but important direction toward exploring CD38 as a potential biomarker of ICB response and CD38 blockade as a combination strategy for chemo-immunotherapy in SCLC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • TMB-H • CD38 expression • CTLA4 expression • PD-L1-L • FOXP3 expression
    |
    cisplatin • etoposide IV
    9ms
    Lactate drives CD38 signaling to promote Epithelial-Mesenchymal Transition through Snail induction in non-small cell lung cancer cells. (PubMed, J Cell Commun Signal)
    The highly expressed CD38 converts NAD + to adenosine through the CD203a/CD73 complex and adenosine binds and activates its receptor A2AR, inducing the expression of Snail and promoting the invasion and metastasis of lung cancer cells. This finding elucidates a new perspective on the interplay between NAD + metabolism and glycolysis in tumor development.
    Journal • IO biomarker
    |
    CD73 (5'-Nucleotidase Ecto) • SNAI1 (Snail Family Transcriptional Repressor 1)
    |
    CD38 expression • CD73 expression
    9ms
    SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Hangzhou Sumgen Biotech Co., Ltd. | Withdrawn --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Jun 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    SG301 IV
    9ms
    B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression (clinicaltrials.gov)
    P=N/A, N=1248, Completed, Northwell Health | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Sep 2023 | Trial primary completion date: Jan 2025 --> Sep 2023
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    CD38 expression
    9ms
    Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell lines in vitro. (PubMed, Front Immunol)
    Daratumumab (dara), a monoclonal antibody (mAb) that targets CD38 results in antibody-dependent cellular cytotoxicity (ADCC) of both multiple myeloma (MM) cells and NK cells. Because NK cells express CD38, XmAb24306 increases dara-mediated NK cell fratricide, but overall does not negatively impact the ADCC activity against a MM cell line likely due to increased NK cell activity of the surviving cells. These data show that XmAb24306 increases direct and ADCC-mediated human NK cell cytotoxicity in vitro.
    Preclinical • Journal • IO biomarker • Tumor cell
    |
    IL15 (Interleukin 15)
    |
    CD38 expression
    |
    Darzalex (daratumumab)
    9ms
    CD38-RyR2 axis-mediated signaling impedes CD8+ T cell response to anti-PD1 therapy in cancer. (PubMed, Proc Natl Acad Sci U S A)
    Knockdown of RyR2 or inhibition of AKT in CD8+ T cells maintained TCF1 levels, induced a sustained anti-tumor response, and enhanced responsiveness to anti-PD1 therapy. Thus, targeting CD38 represents a potential strategy to improve the efficacy of anti-PD1 treatment in cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    CD38 expression • CD8 expression
    10ms
    Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
    P2, N=50, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Nov 2023
    Enrollment open • Trial initiation date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    10ms
    CD38-Specific Gallium-68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET. (PubMed, Adv Sci (Weinh))
    In conclusion, [68 Ga]Ga-AJ206 exhibits the salient features required for clinical translation, providing CD38-specific high-contrast images in multiple models of MM. [68 Ga]Ga-AJ206-PET could be useful for quantifying total CD38 levels and pharmacodynamics during therapy to evaluate approved and new therapies in MM and other diseases with CD38 involvement.
    PK/PD data • Journal • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    Darzalex (daratumumab) • Sarclisa (isatuximab-irfc)
    10ms
    Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, PETHEMA Foundation
    New P2 trial
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    10ms
    CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFNγ-induced CD38 expression. (PubMed, Blood)
    Critically, while BN-CD38 showed significant in vivo efficacy across multiple disseminated AML cell lines and patient derived xenograft models, it did not affect normal hematopoietic stem cell clonogenicity and the development of multi-lineage human immune cells in CD34pos humanized mice. Taken together, this study provides important insights to target and eliminate AML LSCs.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD38 (CD38 Molecule) • IRF1 (Interferon Regulatory Factor 1)
    |
    CD38 expression • IFNG expression • IRF1 expression
    10ms
    Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma. (PubMed, Nat Commun)
    Inhibition of H3K27me3 with an EZH2 inhibitor resulted in CD38 and CD48 upregulation and restored sensitivity to Daratumumab. These findings suggest KDM6A loss as a mechanism of Daratumumab resistance and lay down the proof of principle for the therapeutic application of EZH2 inhibitors, one of which is already FDA-approved, in improving MM responsiveness to Daratumumab.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule) • KDM6A (Lysine Demethylase 6A) • CD48 (CD48 Molecule)
    |
    CD38 expression
    |
    Darzalex (daratumumab)
    11ms
    A first-in-human study to investigate subcutaneous doses of SAR444559 compared with placebo in healthy adult participants. (ACTRN12622001387718)
    P1, N=102, Terminated, Sanofi-Aventis Australia Pty Ltd | Active, not recruiting --> Terminated
    Trial termination
    |
    CD38 expression
    11ms
    Robinetin Alleviates Metabolic Failure in Liver through Suppression of p300-CD38 Axis. (PubMed, Biomol Ther (Seoul))
    The chromatin immunoprecipitation (ChIP) assay showed that p300 occupancy on the promoter region of CD38 was significantly decreased, and H3K9 acetylation levels were diminished in lipid-accumulated AML-12 cells treated with RBN. RBN improves the pathogenic features of metabolic failure by suppressing the p300-CD38 axis through its anti-HAT activity, which suggests that RBN can be used as a new phytoceutical candidate for preventing or improving this condition.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    11ms
    Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate preclinical efficacy and safety in Multiple Myeloma. (PubMed, Cancer Immunol Res)
    Further, we provide evidence that, unlike anti-CD38 CAR-T, which elicited a rapid immune reaction against hematopoietic cells in a humanized mouse model, DCAR-T showed no signs of toxicity. Thus, DCAR-T could provide a safe and efficient alternative to anti-BCMA CAR-T to treat MM patients.
    Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
    |
    SLAMF7 (SLAM Family Member 7)
    |
    CD38 expression
    11ms
    NCI-2022-03039: Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Suspended --> Recruiting
    Enrollment open
    |
    CD38 expression
    |
    Darzalex (daratumumab)
    11ms
    Cluster of Differentiation 38 Protein Significantly Adds to the Prognostic Value of Cytogenetic Risk in Patients with Acute Myeloid Leukemia. (PubMed, Oman Med J)
    Patients with poor cytogenetic risk were associated with significantly shorter median overall survival when compared to favorable and intermediate cytogenetic risk (p =0.010). The expression of CD38 significantly adds to the prognostic value of cytogenetic risk stratification at diagnosis of AML patients.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression • CD38 positive
    11ms
    FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Dec 2025 --> Jan 2024
    Trial primary completion date • Combination therapy
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538
    11ms
    NCI-2022-03039: Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    CD38 expression
    |
    Darzalex (daratumumab)
    12ms
    CD38 gene polymorphism rs1130169 contribution to the increased gene expression and risk of colorectal cancer (pilot study). (PubMed, Mol Biol Rep)
    This study indicated biological significance of rs1130169 variations that can alter differences in CRC risk by regulating CD38 gene expression.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression • CD38 positive
    12ms
    Impact of Smoking and Its Cessation on Systemic and Airway Immune Activation (clinicaltrials.gov)
    P=N/A, N=53, Completed, Boston Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    CD8 (cluster of differentiation 8) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD28 (CD28 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CCR2 (C-C Motif Chemokine Receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8) • ITGAX (Integrin Subunit Alpha X) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • PTGDR2 (Prostaglandin D2 Receptor 2)
    |
    CD38 expression • IL2RA expression
    12ms
    Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells. (PubMed, Int J Mol Sci)
    CD38 knock-out CAR NK cells also demonstrated significantly higher levels of NK activation markers in co-cultures with both untreated and αCD38-treated MM cell lines. These NAM-cultured NK cells with the combined genetic approach of CD38 knockout and addition of CD38 CAR represent a promising immunotherapeutic tool to target MM.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    1year
    Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies. (PubMed, Iran J Immunol)
    The in vitro findings indicated that the anti-CD38 CAR-NK cells have the potential to be used as an off-the-shelf therapeutic strategy against CD38-positive malignancies. It is recommended that the present engineered NK cells undergo additional preclinical investigations before they can be considered for subsequent clinical trial studies.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • GZMB (Granzyme B) • ANXA5 (Annexin A5)
    |
    CD38 expression • CD38 positive
    1year
    Microarray-Based CD38 Peptide Probe Screening for Multiple Myeloma Imaging. (PubMed, Mol Pharm)
    Peptide probes were labeled with indocyanine green (ICG) dye and Ga-DOTA, which were injected into a CD38-positive Ramos tumor-bearing mouse via its tail vein, and small animal fluorescence and positron emission tomography (PET) imaging showed that the peptide probes could show specific enrichment in the tumor tissue. Our study shows that a microchip-based screening of peptide probes can be used as a promising imaging tool for MM diagnosis.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression • CD38 positive